Estonia-based digital therapeutics company Epillo Health Systems has launched its latest line of clinical solutions. It comprises EHR systems for clinics and pharmacies and a mobile app for patients, which is now available in Singapore, Malaysia, India and the US.
WHAT IT DOES
The web-based INTRx Clinical system helps clinicians manage patient portfolio and health with features such as e-prescribing, teleconsultations, patient coordinated care, monitoring and analytics, diet and lab tests, among others. It also handles administrative and financial workflows, as well as appointments.
It is connected with the Epillo mobile app, a connectivity tool that provides patients access to their medical records and prescriptions. It also allows them to conduct follow-ups and bookings, engage in video consultations with their attending physicians and access wellbeing management features.
In an interview with MobiHealthNews, the company said the Epillo mobile app will have a “premium subscription model” that will offer advanced drug-drug and drug-food interaction analysis for patients, as well as premium health or wellbeing assessment tools and monitoring features.
The Android version of the app is already available for download while the iOS version is expected to come out by the end of this week.
Additionally, the INTRx Pharma system is a prescription order management and inventory management solution for pharmacies.
WHY IT MATTERS
Adopting “newer and safer” technologies is needed to boost healthcare infrastructure, according to Epillo CEO Aasif Shah.
“The adoption of the blockchain distributed ledger model in Epillo’s digital health solutions will create an unprecedented level of accuracy, privacy, and security in health data for healthcare stakeholders and patients,” the company official said in a statement.
So far, more than 200 doctors providing telemedicine services have joined the Epillo system. The company said it is targeting 500,000 downloads of its mobile app by the end of the year.
THE LARGER TREND
Epillo reported in March that it got appraised at $150 million for its AI-based medical and pharmacological application called INTRx. The technology, it said, can run drug and food constituent interaction analysis, making it a continuous digital therapeutic device that increases the efficiency of patient prescription plans. It can also predict drug-food and drug-drug interactions that will prevent adverse drug effects.
The patent for INTRx is still pending in 27 states of the European Union and 153 countries through the United States Patent and Trademark Office.
In other news, DrChrono introduced in February an open FHIR API that will allow the seamless transfer of patients’ data from its OnPatient personal health record platform to Apple Health.
ON THE RECORD
“It is time to break the silos. This application development took us almost five years to streamline the detailing of the connected healthcare ecosystem. The influx of information moving across from patients to doctors to service providers is increasing post-pandemic. One needs to have an integrated approach on a real-time basis to streamline healthcare practice and we are happy to present a solution in a simplified format,” Dr Bhupinder Singh, Epillo board chairman, said.